#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

### FORM 8-K

#### CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 17, 2020

# **BIO-PATH HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

Delaware	001-36333	87-0652870
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4710 Bellaire Boulevard, S	Suite 210, Bellaire, Texas	77401
(Address of principa		(Zip Code)
(I	(832) 742-1357 Registrant's Telephone Number, Including Area Co	de)
(Forme	er Name or Former Address, if Changed Since Last	Report)
Check the appropriate box below if the Form 8-K fili provisions:	ng is intended to simultaneously satisfy the filing o	bligation of the registrant under any of the following
Securities registered pursuant to Section 12(b) of the	Act:	
Title of each class Common Stock, par value \$0.001 per sha	Trading Symbol re BPTH	Name of each exchange on which registered The Nasdaq Capital Market
Indicate by check mark whether the registrant is an enchapter) or Rule 12b-2 of the Securities Exchange Act		f the Securities Act of 1933 (§230.405 of this
		Emerging growth company □
If an emerging growth company, indicate by check mew or revised financial accounting standards provide		

### Item 5.07 Submission of Matters to a Vote of Security Holders.

Bio-Path Holdings, Inc. (the "Company") held its 2020 annual meeting (the "2020 Annual Meeting") of stockholders on December 17, 2020 in The Woodlands, Texas. At the 2020 Annual Meeting, the Company's stockholders: (i) elected the five persons listed below under Proposal 1 to serve as directors of the Company, to hold office until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified; (ii) ratified and approved the appointment of Ernst & Young, LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2020; and (iii) approved, on a non-binding advisory basis, the Rule 14a-8 stockholder proposal regarding a compensation study. The following describes the results of the voting at the 2020 Annual Meeting:

<u>Proposal 1</u>: For the election of directors of the Company, to hold office until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified:

Name of Nominee	Shares Voted "For"	Shares Voted "Against"	Shares Withheld	Shares Abstained	Broker Non-Votes
Peter H. Nielsen	617,104		71,170		2,577,612
Heath W. Cleaver	582,891		105,383		2,577,612
Paul D. Aubert	585,158		103,116		2,577,612
Martina Molsbergen	585,337		102,937		2,577,612
Douglas P. Morris	629,855		58,419		2,577,612

<u>Proposal 2</u>: For the ratification and approval of the appointment of Ernst & Young, LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2020:

Shares Voted	<b>Shares Voted</b>	Shares	Shares	Broker
"For"	"Against"	Withheld	Abstained	Non-Votes
3,138,152	82,919		44,815	

<u>Proposal 3</u>: For the non-binding advisory approval of the Rule 14a-8 stockholder proposal regarding a compensation study:

Shares Voted	Shares Voted "Against"	Shares	Shares	Broker
"For"		Withheld	Abstained	Non-Votes
395,266	225,286		67,722	2,577,612

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 18, 2020

# **BIO-PATH HOLDINGS, INC.**

By: /s/ Peter H. Nielsen

Peter H. Nielsen President and Chief Executive Officer